The relation between urinary angiotensinogen and proteinuria in renal AA amyloidosis patients

Amyloid

Volumn 19, Issue 1, 2012, Pages 28-32

  Kutlugün, Aysun Aybal ^a   Altun, Bulent ^a   Aktan, Umit ^a   Turkmen, Ercan ^a   Altindal, Mahmut ^a   Yildirim, Tolga ^a   Yilmaz, Rahmi ^a   Arici, Mustafa ^a   Erdem, Yunus ^a   Turgan, Cetin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Amyloidosis AA; Angiotensinogen; Proteinuria; Renin angiotensin system

Indexed keywords

AMLODIPINE; ANGIOTENSIN ANTAGONIST; ANGIOTENSINOGEN; CARVEDILOL; COLCHICINE; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RENIN INHIBITOR; SERUM ALBUMIN; TRIACYLGLYCEROL;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RENAL AA AMYLOIDOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS;

ADULT; AMYLOIDOSIS; ANGIOTENSINOGEN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CREATININE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROTEINURIA; REGRESSION ANALYSIS; SERUM AMYLOID A PROTEIN;

EID: 84857210314     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2012.654530     Document Type: Article

References (39)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909. (Pubitemid 27408573)
2. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 1991;70:246-256.
3. Gertz MA. Secondary amyloidosis (AA). J Intern Med 1992;232:517-518. (Pubitemid 23024323)
4. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, et al.; AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Disease. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-1140. (Pubitemid 34205814)
5. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-762.
6. Praga M, Hernndez E, Montoyo C, Andrs A, Ruilope LM, Rodicio JL. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992;20:240-248.
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-1462. (Pubitemid 23335891)
8. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87. (Pubitemid 32661190)
9. Dilek K, Usta M, Ersoy A, Ozdemir B, Yavuz M, Glll M, Yurtkuran M. Long-term effects of losartan on proteinuria and renal function in patients with renal amyloidosis. Scand J Urol Nephrol 2002;36:443-446. (Pubitemid 36169504)
10. Odabas AR, Cetinkaya R, Selcuk Y, Bilen H. Effect of losartan treatment on the proteinuria in normotensive patients having proteinuria due to secondary amyloidosis. Ups J Med Sci 2001;106:183-188. (Pubitemid 33643801)
11. Velez JC. The importance of the intrarenal renin-angiotensin system. Nat Clin Pract Nephrol 2009;5:89-100.
12. Ketteler M, Noble NA, Border WA: Transforming growth factor-I3 and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis? Ann Rev Physiol 1995;57:279-295.
13. Ruiz-Ortega M, Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997;52:1497-1510. (Pubitemid 28032053)
14. Kobori H, Nishiyama A, Harrison-Bernard LM, Navar LG. Urinary angiotensinogen as an indicator of intrarenal Angiotensin status in hypertension. Hypertension 2003;41:42-49. (Pubitemid 36056790)
15. Kobori H, Alper AB Jr, Shenava R, Katsurada A, Saito T, Ohashi N, Urushihara M, et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension 2009;53:344-350.
16. Urushihara M, Kondo S, Kagami S, Kobori H. Urinary angiotensinogen accurately reflects intrarenal Renin-Angiotensin system activity. Am J Nephrol 2010;31:318-325.
17. Saito T, Urushihara M, Kotani Y, Kagami S, Kobori H. Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am J Med Sci 2009;338:478-480.
18. Nishiyama A, Konishi Y, Ohashi N, Morikawa T, Urushihara M, Maeda I, Hamada M, et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol Dial Transplant 2011;26:170-177.
19. Cohen EP, Kobori H, Moulder JE, Fish BL, Navar LG. Intrarenal angiotensinogen in radiation nephropathy (abstract) J Invest Med 2005;53:S288.
20. Rohrwasser A, Morgan T, Dillon HF, Zhao L, Callaway CW, Hillas E, Zhang S, et al. Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension 1999;34:1265-1274. (Pubitemid 30002393)
21. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal reninangiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251-287. (Pubitemid 47481436)
22. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002;39:129-134. (Pubitemid 34098101)
23. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470. (Pubitemid 29135798)
24. Ruiz-Ortega M, Gonzlez S, Sern D, Condom E, Bustos C, Largo R, Gonzlez E, et al. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 1995;48:1778-1791.
25. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005;1753:11-22. (Pubitemid 41597427)
26. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-29. (Pubitemid 32709735)
27. Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis; a 10-21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol 1993;20:2051-2057. (Pubitemid 24043128)
28. Ozen S. Renal amyloidosis in familial Mediterranean fever. Kidney Int 2004;65:1118-1127. (Pubitemid 38258281)
29. Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Combe B, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-2024. (Pubitemid 36828697)
30. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-2371. (Pubitemid 46883770)
31. Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper ME, Wilkinson-Berka JL, Gilbert RE. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001;44:878-882. (Pubitemid 32642461)
32. Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 2007;29:1803-1824. (Pubitemid 350214460)
33. Li J, Zhou C, Yu L, Wang H. Renal protective effects of blocking the intrarenal renin-angiotensin system. Hypertens Res 1999;22:223-228. (Pubitemid 29450314)
34. Lee EY, Shim MS, Kim MJ, Hong SY, Shin YG, Chung CH. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Exp Mol Med 2004;36:65-70. (Pubitemid 38374726)
35. Vieitez P, Gmez O, Uceda ER, Vera ME, Molina-Holgado E. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy. J Renin Angiotensin Aldosterone Syst 2008;9:96-102. (Pubitemid 351998217)
36. Ruggenenti P, Remuzzi G. Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease. Curr Opin Nephrol Hypertens 1997;6:489-495. (Pubitemid 27397885)
37. el Nahas AM. Renal scarring: the role of angiotensin II. Nephrol Dial Transplant 1995;10 Suppl 9: 28-32
38. Aybal Kutlugun A, Altun B, Buyukasik Y, Aki T, Turkmen E, Altindal M, Yildirim T, et al. Elevated urinary angiotensinogen a marker of intrarenal renin angiotensin system in hypertensive renal transplant recipients: does it play a role in development of proteinuria in hypertensive renal transplant patients? Transpl Int 2012;25:13-18.
39. Kobori H, Ohashi N, Katsurada A, Miyata K, Satou R, Saito T, Yamamoto T. Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens 2008;2:349-354.